Labiotech.eu

News and Trends 10 Nov 2022

Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies

Precision oncology company, Parthenon Therapeutics, and ImaginAb Inc., a global biotech have entered into a multi-year, non-exclusive license and supply agreement. Under the agreement terms, Parthenon will use ImaginAb’s CD8 ImmunoPET imaging technology in its phase 1 trial evaluating its lead compound, PRTH-101, which is expected to begin in 2023. ImaginAb is developing 89Zr crefmirlimab […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Sanofi and GSK Covid-19 booster vaccine approved by European Commission

Sanofi and GSK’s Covid booster vaccine has been approved in Europe. After the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn Beta, the vaccine was approved by the European Commission, as a booster for the prevention of Covid-19 in adults 18 years of age and older. […]

November 10, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Promising drug candidate discovered for prevention of type 1 diabetes

According to a new study in Finland, type 1 diabetes could be prevented by inhibiting a gene associated with the onset of the disease. A drug based on the same mechanism has already been approved for the treatment of another autoimmune disease, psoriasis, in the U.S., which may boost the development of drug therapies for […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

Startup Scout 10 Nov 2022

ResQ Biotech is using bacteria to discover Alzheimer’s treatments

Protein misfolding underlies many incurable conditions such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The Greek startup ResQ Biotech is harnessing bacteria to test potential peptide treatments for these diseases. There are many diseases that involve the faulty processing of proteins in the cell, leading the proteins to clump together and damage the tissue. […]

November 10, 2022 - 4 minutesmins - By Jonathan Smith

More News! 10 Nov 2022

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

Breye Therapeutics ApS a biopharmaceutical company developing therapies for retinal vascular diseases today (November 10) has closed a seed financing of €4 million led by Novo Holdings and Sound Bioventures. Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and is the leading cause of blindness among working-age adults. Age-related macular degeneration (AMD) […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Avstera receives funding for cancer programs

Avstera Therapeutics Corp. has announced the completion of its seed round to advance its lead cancer programs geared toward targeting solid tumors. The company intends to use the $4.55 million proceeds to enable its lead highly specific HDAC6i for IND filing targeting locally advanced and metastatic solid tumors by the end of next year. “Tumor […]

November 10, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Researchers develop new nanoparticle to deliver drugs direct to macrophages

How can a drug be delivered exactly where it is needed, while limiting the risk of side effects? The use of nanoparticles to encapsulate a drug to protect it and the body until it reaches its point of action is being increasingly studied. However, this requires identifying the right nanoparticle for each drug according to […]

November 10, 2022 - 4 minutesmins - By Jim Cornall

More News! 10 Nov 2022

Novo Nordisk supports Plant2Food platform with €27M funding

Novo Nordisk Foundation will support new open collaborative platform, Plant2Food, to accelerate the development of plant-based foods with up to €27 million ($26.9m) over the next five years. The platform, Plant2Food, will include researchers and companies collaborating and exploring complex challenges within plant and food science and sharing new knowledge across sectors – without taking […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Ascentage Pharma gets Chinese approval for solid tumor study

Ascentage Pharma says its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluations (CDE) of China National Medical Products Administration (NMPA) to enter a phase I study in patients with advanced solid tumors or hematologic malignancies. Following the recent clearance for the study in the […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Novel branched lipid boosts mRNA delivery to cells

A novel branched lipid that is highly stable in storage and is highly efficient in delivering mRNA to cells has been developed. Messenger RNA (mRNA) is a biological molecule that transfers the information coded by genes in the nucleus to the cytoplasm for protein synthesis by ribosomes. mRNA sequences can be designed to encode specific […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment

Minoryx Therapeutics and Neuraxpharm Group have announced the completion of a strategic license agreement. Minoryx is a biotech company that focuses on the development of treatments for orphan central nervous system (CNS) disorders while the Neuraxpharm Group is a pharmaceutical company focused on CNS therapies. Under the agreement, Minoryx grants Neuraxpharm exclusive European rights to […]

November 10, 2022 - 3 minutesmins - By Liza Laws

The red cancer cell uses the white protein Memo1 to bind the green copper ions.

News and Trends 10 Nov 2022

Looking for cancer clues? Copper may open new drug treatment doors

For cancer cells to grow and spread around the human body, they need proteins that bind copper ions. New research about how cancer-related proteins bind the metal and how they interact with other proteins may open up potential new drug targets in the fight against cancer. Human cells need small amounts of the metal copper […]

November 10, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies

Sanofi and GSK Covid-19 booster vaccine approved by European Commission

Promising drug candidate discovered for prevention of type 1 diabetes

ResQ Biotech is using bacteria to discover Alzheimer’s treatments

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

Avstera receives funding for cancer programs

Researchers develop new nanoparticle to deliver drugs direct to macrophages

Novo Nordisk supports Plant2Food platform with €27M funding

Ascentage Pharma gets Chinese approval for solid tumor study

Novel branched lipid boosts mRNA delivery to cells

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment

Looking for cancer clues? Copper may open new drug treatment doors

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!